Huapont Life Sciences Co.,Ltd. (SHE:002004)
China · Delayed Price · Currency is CNY 4.980
+0.050 (1.01%)
Apr 29, 2026, 3:04 PM CST
Huapont Life Sciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 11,510 | 11,512 | 11,508 | 11,409 | 13,021 | 12,290 |
Other Revenue | - | - | 156.83 | 186.02 | 211.45 | 141.06 |
| 11,510 | 11,512 | 11,665 | 11,595 | 13,232 | 12,431 | |
Revenue Growth (YoY) | -0.52% | -1.31% | 0.60% | -12.38% | 6.44% | 14.29% |
Cost of Revenue | 7,295 | 7,262 | 7,827 | 7,208 | 7,971 | 7,759 |
Gross Profit | 4,215 | 4,251 | 3,838 | 4,387 | 5,261 | 4,672 |
Selling, General & Admin | 2,296 | 2,344 | 2,259 | 2,550 | 2,904 | 2,753 |
Research & Development | 310.78 | 341.62 | 375.32 | 419.14 | 385.24 | 329.47 |
Other Operating Expenses | 65.51 | 57.45 | 114.96 | 103.47 | 89.41 | 80.78 |
Operating Expenses | 2,672 | 2,743 | 2,770 | 3,080 | 3,386 | 3,188 |
Operating Income | 1,543 | 1,507 | 1,068 | 1,307 | 1,875 | 1,484 |
Interest Expense | - | - | -349.97 | -343.7 | -434.01 | -461.68 |
Interest & Investment Income | 66.99 | 60.32 | 69.66 | 92.75 | 529.44 | 380.87 |
Currency Exchange Gain (Loss) | - | - | 29.81 | 46.5 | 153.25 | -31.74 |
Other Non Operating Income (Expenses) | -364.4 | -340.65 | -32.98 | -43.03 | -42.16 | -55.59 |
EBT Excluding Unusual Items | 1,245 | 1,227 | 784.79 | 1,059 | 2,082 | 1,316 |
Impairment of Goodwill | - | - | -707.56 | -208.16 | -491.85 | -29.36 |
Gain (Loss) on Sale of Investments | 4.23 | 6.66 | -194.06 | 1.2 | -4.84 | 8.52 |
Gain (Loss) on Sale of Assets | 9.62 | 10.05 | 3.75 | 28.11 | -21.26 | -22.43 |
Asset Writedown | -189.92 | -185.87 | -108.59 | -88.96 | -31.51 | -93.3 |
Other Unusual Items | - | - | 61.16 | 101.04 | 90.16 | 101.87 |
Pretax Income | 1,069 | 1,058 | -160.51 | 892.39 | 1,623 | 1,281 |
Income Tax Expense | 187.81 | 176.64 | 182.09 | 215.46 | 495.49 | 361.04 |
Earnings From Continuing Operations | 881.35 | 881.23 | -342.59 | 676.93 | 1,127 | 920.2 |
Minority Interest in Earnings | -197.67 | -168.04 | 43.6 | -374.81 | -693.72 | -252.4 |
Net Income | 683.68 | 713.19 | -298.99 | 302.12 | 433.48 | 667.81 |
Net Income to Common | 683.68 | 713.19 | -298.99 | 302.12 | 433.48 | 667.81 |
Net Income Growth | - | - | - | -30.30% | -35.09% | 2.47% |
Shares Outstanding (Basic) | 1,973 | 1,973 | 1,975 | 1,980 | 1,980 | 1,980 |
Shares Outstanding (Diluted) | 1,973 | 1,973 | 1,975 | 1,980 | 1,980 | 1,980 |
Shares Change (YoY) | -0.05% | -0.10% | -0.25% | -0.02% | 0.02% | 0.25% |
EPS (Basic) | 0.35 | 0.36 | -0.15 | 0.15 | 0.22 | 0.34 |
EPS (Diluted) | 0.35 | 0.36 | -0.15 | 0.15 | 0.22 | 0.34 |
EPS Growth | - | - | - | -30.29% | -35.10% | 2.21% |
Free Cash Flow | 1,698 | 1,458 | 669.02 | 305.35 | 1,277 | 13.19 |
Free Cash Flow Per Share | 0.86 | 0.74 | 0.34 | 0.15 | 0.65 | 0.01 |
Dividend Per Share | - | - | - | 0.220 | 0.220 | 0.220 |
Gross Margin | 36.62% | 36.92% | 32.90% | 37.83% | 39.76% | 37.58% |
Operating Margin | 13.40% | 13.09% | 9.16% | 11.27% | 14.17% | 11.94% |
Profit Margin | 5.94% | 6.19% | -2.56% | 2.61% | 3.28% | 5.37% |
Free Cash Flow Margin | 14.75% | 12.66% | 5.73% | 2.63% | 9.65% | 0.11% |
EBITDA | 2,592 | 2,532 | 1,995 | 2,165 | 2,647 | 2,200 |
EBITDA Margin | 22.52% | 22.00% | 17.10% | 18.67% | 20.00% | 17.70% |
D&A For EBITDA | 1,049 | 1,025 | 926.8 | 858.19 | 771.15 | 716.37 |
EBIT | 1,543 | 1,507 | 1,068 | 1,307 | 1,875 | 1,484 |
EBIT Margin | 13.40% | 13.09% | 9.16% | 11.27% | 14.17% | 11.94% |
Effective Tax Rate | 17.57% | 16.70% | - | 24.14% | 30.54% | 28.18% |
Revenue as Reported | - | - | 11,665 | 11,595 | 13,232 | 12,431 |
Advertising Expenses | - | - | 410.08 | 610.81 | 758.7 | 887.58 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.